{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001603","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.645573+00:00","generated_at":"2026-05-28T04:48:33.324612+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement","bullets":["Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.","90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.","Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.","Company also published cancer presentation on galectin antagonists in cancer.","CEO states findings herald significant shift in cancer treatment paradigms."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001603","json":"https://secwatch.observer/filing/0001493152-25-001603.json","markdown":"https://secwatch.observer/filing/0001493152-25-001603.md","text":"https://secwatch.observer/filing/0001493152-25-001603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/0001493152-25-001603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:48:33.324612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}